The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

(2017) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

(2015) Bipasha Mukherjee et al.   NEOPLASIA

Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?

(2013) Gunter von Minckwitz et al.   BREAST

D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

(2013) K. Merenbakh-Lamin et al.   CANCER RESEARCH

mTOR inhibitors in advanced breast cancer: Ready for prime time?

(2013) Lesley-Ann Martin et al.   CANCER TREATMENT REVIEWS

Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer

(2013) A. Bardia et al.   CLINICAL CANCER RESEARCH

Tackling the Diversity of Triple-Negative Breast Cancer

(2013) N. C. Turner et al.   CLINICAL CANCER RESEARCH

Doxorubicin Enhances Nucleosome Turnover around Promoters

(2013) Fan Yang et al.   CURRENT BIOLOGY

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved

(2013) Per Eystein Lønning et al.   ENDOCRINE-RELATED CANCER

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

(2013) Jean Charles Soria et al.   EUROPEAN JOURNAL OF CANCER

Reply to M. Gallén et al and R.S. Midgley et al

(2013) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

(2013) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

(2013) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic targets in triple negative breast cancer

(2013) Sandra A O'Toole et al.   JOURNAL OF CLINICAL PATHOLOGY

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

(2013) Brian D Lehmann et al.   JOURNAL OF PATHOLOGY

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

(2013) P E Lønning et al.   ONCOGENE

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1

(2013) Jonathan T. Sims et al.   PLoS One

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer

(2012) M. T. Weigel et al.   ANNALS OF ONCOLOGY

Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)

(2012) Makoto Kubo et al.   BREAST CANCER RESEARCH AND TREATMENT

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

(2012) Anna-Maria Jegg et al.   BREAST CANCER RESEARCH AND TREATMENT

Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials

(2012) John R. Mackey et al.   CANCER TREATMENT REVIEWS

The Life History of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

(2012) A. Kathleen McClendon et al.   CELL CYCLE

Biomarker and Pharmacologic Evaluation of the  -Secretase Inhibitor PF-03084014 in Breast Cancer Models

(2012) C. C. Zhang et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Targeting Hsp90--Who Benefits and Who Does Not

(2012) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds

(2012) A. Palmeira et al.   CURRENT MEDICINAL CHEMISTRY

Tumor vasculature: the Achilles' heel of cancer?

(2012) Tor-Christian Aase Johannessen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance

(2012) Rocío García-Becerra et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

(2012) Jeffry L. Dean et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics

(2012) Kiran Mahajan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

DNA Methylation As a Clinical Marker in Oncology

(2012) Jean-Pierre Issa   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

Appropriate Design of Prospective Studies

(2012) Jung-Hye Choi et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

(2012) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a KRAS Mutation or FGFR1 Gene Amplification

(2012) J. M. Balko et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy

(2012) Farah L. Rehman et al.   Cancer Discovery

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine

(2011) Amit Khatri et al.   AAPS Journal

Src: a potential target for the treatment of triple-negative breast cancer

(2011) D. Tryfonopoulos et al.   ANNALS OF ONCOLOGY

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

(2011) Stacy Moulder et al.   CANCER

Functional Activation of the Estrogen Receptor-  and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole

(2011) G. J. Sabnis et al.   CANCER RESEARCH

Genome-Wide DNA Methylation Profiling of CpG Islands in Breast Cancer Identifies Novel Genes Associated with Tumorigenicity

(2011) V. K. Hill et al.   CANCER RESEARCH

Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer

(2011) X. Hou et al.   CANCER RESEARCH

Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell Types

(2011) D. Iliopoulos et al.   CANCER RESEARCH

Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor-Treated ER-Positive Breast Cancer

(2011) Z. Ghazoui et al.   CLINICAL CANCER RESEARCH

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

(2011) S. Modi et al.   CLINICAL CANCER RESEARCH

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer

(2011) C. A. Lange et al.   ENDOCRINE-RELATED CANCER

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

(2011) C. Thangavel et al.   ENDOCRINE-RELATED CANCER

Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer

(2011) Amy Guppy et al.   Future Oncology

The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology

(2011) Suzanne A. Eccles   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

Targeted therapies for breast cancer

(2011) Michaela J. Higgins et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

(2011) Todd W. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer

(2011) Dan R Robinson et al.   NATURE MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

(2011) B Weigelt et al.   ONCOGENE

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer

(2011) J. Baselga   ONCOLOGIST

Significance of ER–Src axis in hormonal therapy resistance

(2010) Sreeram Vallabhaneni et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.

(2010) RS Finn et al.   CANCER RESEARCH

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

(2010) B. Schoeberl et al.   CANCER RESEARCH

Simultaneous targeting of estrogen receptor and HER2 in breast cancer

(2010) Hatem A Azim Jr et al.   Expert Review of Anticancer Therapy

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

(2010) Joleen Hubbard et al.   INVESTIGATIONAL NEW DRUGS

Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance

(2010) Gauri Sabnis et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

EGFR Signaling and Drug Discovery

(2010) Georg Lurje et al.   ONCOLOGY

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

(2010) J. J. Wallin et al.   Science Translational Medicine

Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis

(2010) Ryan Morrison et al.   Journal of Oncology

Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance

(2009) C. Wong et al.   CANCER RESEARCH

Notch signalling in cancer stem cells

(2009) Victoria Bolós et al.   Clinical & Translational Oncology

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

(2009) E. Caldas-Lopes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Eag1: An Emerging Oncological Target

(2008) L. A. Pardo et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

(2008) A. Sawai et al.   CANCER RESEARCH

Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches

(2008) P. Rizzo et al.   CANCER RESEARCH

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

(2008) A. N. Tse et al.   CLINICAL CANCER RESEARCH

A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

(2008) S. S. Ramalingam et al.   CLINICAL CANCER RESEARCH

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

(2008) P.E. Lønning   EUROPEAN JOURNAL OF CANCER

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer

(2008) Quanri Jin et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

(2008) L S Steelman et al.   ONCOGENE

The PTEN–PI3K pathway: of feedbacks and cross-talks

(2008) A Carracedo et al.   ONCOGENE